# Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

> **NCT05145816** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 37 (estimated)

## Conditions studied

- AL Amyloidosis
- Amyloidosis

## Interventions

- **DRUG:** Belantamab mafodotin 2.5 mg/kg (8 weeks)
- **DRUG:** Belantamab mafodotin 1.9 mg/kg (8 weeks)
- **DRUG:** Belantamab mafodotin 1.4 mg/kg (12 weeks)
- **DRUG:** Belantamab mafodotin 1.9 mg/kg (12 weeks)
- **DRUG:** Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages
- **DRUG:** Belantamab mafodotin 1.0 mg/kg (12 weeks)

## Key facts

- **NCT ID:** NCT05145816
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-15
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145816, "Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05145816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*